<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Neurology Solutions — ArcaScience | AI-Driven Benefit-Risk Analysis</title>
  <meta name="description" content="ArcaScience's AI-driven benefit-risk analysis platform for Neurology. 15B+ neurology data points, CNS-specific AI models, and regulatory-grade outputs for neurodegenerative and neuropsychiatric drug development.">

  <!-- Fonts: self-hosted for performance -->
  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>

  <!-- Global CSS (from build) -->
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <!-- Reduced motion detection before paint -->
  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <!-- SCROLL PROGRESS BAR -->
  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">

      <!-- Logo -->
      <a href="/" aria-label="ArcaScience home">
        <img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32">
      </a>

      <!-- Nav Links -->
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>

        <!-- Platform dropdown -->
        <div style="position: relative;">
          <a href="/platform" class="arca-nav-link">Platform</a>
        </div>

        <!-- Solutions dropdown — ACTIVE -->
        <div style="position: relative;">
          <a href="/solutions" class="arca-nav-link is-active">Solutions</a>
        </div>

        <a href="/science" class="arca-nav-link">Science</a>
        <a href="/evidence" class="arca-nav-link">Evidence</a>
        <a href="/company" class="arca-nav-link">Company</a>
        <a href="/resources" class="arca-nav-link">Resources</a>
      </div>

      <!-- Header CTA -->
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">
        Talk to a Scientist
      </a>
    </div>
  </nav>

  <!-- Spacer for fixed nav -->
  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- SECTION 1: BREADCRUMB + DARK HERO -->
    <section class="arca-bg-blue-900" style="padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">

        <!-- Breadcrumb -->
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solutions" style="color: rgba(255,255,255,0.65); text-decoration: none;">Solutions</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solutions/therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Neurology</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">
            Therapeutic Area Solutions
          </p>
          <h1 class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            Neurology Benefit-Risk Analysis
          </h1>
          <p class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            Advanced BRA for neurologic therapies — complex CNS safety profiles, blood-brain barrier considerations, cognitive endpoint measurement, and long-term neurodegenerative treatment monitoring across Alzheimer's, Parkinson's, MS, and epilepsy programs.
          </p>
          <a href="/contact?ta=neurology" class="arca-btn-primary-inverted">
            Request Neurology Briefing
          </a>
        </div>

      </div>
    </section>

    <!-- SECTION 2: DATA COVERAGE STATS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="15000000000" data-countup-suffix="+">0</span>
            <p class="arca-caption">Neurology-specific adverse event records</p>
          </div>

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="6200" data-countup-suffix="+">0</span>
            <p class="arca-caption">Neurology clinical trials analyzed</p>
          </div>

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="12" data-countup-suffix="+">0</span>
            <p class="arca-caption">CNS regulatory submissions supported</p>
          </div>

          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="8" data-countup-suffix="+">0</span>
            <p class="arca-caption">Years of post-marketing CNS surveillance data</p>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 3: TA-SPECIFIC CHALLENGE SECTION -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Unique Challenges</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">
            Why Neurology BRA is Different
          </h2>
          <p class="arca-body-lg arca-text-grey-600">
            Neurologic therapies present distinct benefit-risk challenges driven by the complexity of the central nervous system, the blood-brain barrier, and the subjective nature of cognitive and behavioral endpoints.
          </p>
        </div>

        <!-- 3 TA-specific challenge cards -->
        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">

          <div class="arca-card" data-animate>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Blood-Brain Barrier Penetration</h3>
            <p class="arca-body-sm arca-text-grey-600">
              CNS drug delivery requires crossing the blood-brain barrier, creating unique PK/PD profiles that complicate dose-response modeling and safety assessment. Off-target CNS effects — including suicidality, somnolence, and seizure risk — require specialized detection algorithms trained on neurological adverse event patterns distinct from peripheral safety signals.
            </p>
          </div>

          <div class="arca-card" data-animate>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Neuropsychiatric Adverse Events</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Neuropsychiatric AEs — depression, psychosis, cognitive decline, behavioral changes — are notoriously difficult to attribute, measure, and differentiate from underlying disease progression. Validated cognitive scales (MMSE, ADAS-Cog, CDR-SB) introduce measurement variability that demands sophisticated statistical approaches to benefit-risk quantification.
            </p>
          </div>

          <div class="arca-card" data-animate>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Cognitive Endpoint Measurement</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Neurodegenerative therapies require years-long treatment courses with endpoints measured on subjective cognitive scales. Disease-modifying therapies for Alzheimer's, Parkinson's, and MS must demonstrate sustained benefit against cumulative risk using innovative extrapolation models, digital biomarkers, and real-world evidence integration from patient registries.
            </p>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 4: PLATFORM CAPABILITIES FOR THIS TA -->
    <section class="arca-bg-grey-50" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">
            How ArcaScience Addresses Neurology BRA Challenges
          </h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">
            Our three integrated modules — Data Intelligence, Decision Intelligence, and Automated Outputs — are configured for Neurology-specific benefit-risk assessment workflows.
          </p>
        </div>

        <!-- 3 module cards with colored tops -->
        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">

          <!-- Module 1: Data Intelligence (teal) -->
          <div class="arca-card arca-card-colored-top is-data" data-animate>
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">
              Neurology Data Coverage
            </h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              Comprehensive neurology data from 6,200+ clinical trials, 15B+ adverse event records, CNS-specific literature from PubMed and Cochrane, and real-world evidence from EHR, claims databases, and Alzheimer's disease registries. Continuous updates with MedDRA coding specific to neurological safety signals including ARIA events, progressive multifocal leukoencephalopathy (PML), suicidality, and treatment-emergent movement disorders.
            </p>
            <a href="/platform/data-intelligence" class="arca-btn-tertiary">
              Explore Data Engine <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

          <!-- Module 2: Decision Intelligence (indigo) -->
          <div class="arca-card arca-card-colored-top is-analytics" data-animate>
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">
              CNS-Specific AI Models
            </h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              6 AI models trained specifically on neurology safety and efficacy patterns, including ARIA detection for anti-amyloid therapies, cognitive endpoint trajectory modeling using ADAS-Cog and CDR-SB data, neuropsychiatric AE causality assessment, and disease progression vs. drug effect differentiation. BRAT framework application with CNS regulatory precedent integration from FDA and EMA neurodegenerative therapy guidance.
            </p>
            <a href="/platform/ai-models" class="arca-btn-tertiary">
              Explore AI Models <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

          <!-- Module 3: Automated Outputs (green) -->
          <div class="arca-card arca-card-colored-top is-output" data-animate>
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">
              Neurology Regulatory Outputs
            </h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              Submission-ready REMS assessments, cognitive safety monitoring reports, PSUR/PBRER with CNS-specific safety sections, and Risk Management Plans formatted for FDA, EMA, and PMDA requirements. Specialized outputs for ARIA monitoring protocols, suicidality risk evaluation reports (C-SSRS integration), PML surveillance summaries, and long-term cognitive safety trend analyses aligned with ICH E2C(R2).
            </p>
            <a href="/platform/outputs" class="arca-btn-tertiary">
              Explore Outputs <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 5: ADVERSE EVENT LANDSCAPE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Safety Intelligence</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">
            Neurology Adverse Event Landscape
          </h2>
          <p class="arca-body-lg arca-text-grey-600">
            Key safety signal categories tracked across neurology development programs, with AI-powered detection and comparative analysis against class-wide CNS safety profiles.
          </p>
        </div>

        <!-- AE category grid -->
        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 16px;">

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">ARIA (Amyloid-Related Imaging Abnormalities)</h4>
            <p class="arca-body-sm arca-text-grey-600">
              ARIA-E (edema) and ARIA-H (hemorrhage) — critical monitoring requirements for anti-amyloid therapies including lecanemab and donanemab, with APOE4 carrier status stratification and serial MRI protocols.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Suicidality & Mood Changes</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Depression, suicidal ideation, and behavioral changes — mandated by FDA class-wide labeling for antiepileptic drugs and requiring Columbia Suicide Severity Rating Scale (C-SSRS) integration in all CNS trials.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Progressive Multifocal Leukoencephalopathy</h4>
            <p class="arca-body-sm arca-text-grey-600">
              PML risk with immunosuppressive MS therapies (natalizumab, fingolimod) — JC virus antibody index stratification and risk algorithm monitoring for treatment decisions and switching strategies.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Cognitive Decline & Sedation</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Treatment-related cognitive impairment, excessive somnolence, and psychomotor slowing — common with antiepileptics, antipsychotics, and dopaminergic therapies affecting daily functioning and driving ability.
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Movement Disorders</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Tardive dyskinesia, extrapyramidal symptoms, impulse control disorders — iatrogenic movement complications from dopaminergic and antipsychotic therapies requiring long-term monitoring with validated scales (AIMS, UPDRS).
            </p>
          </div>

          <div class="arca-card" style="padding: var(--space-5); border-left: 3px solid var(--indigo-500);" data-animate>
            <h4 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Seizure Risk & Neurotoxicity</h4>
            <p class="arca-body-sm arca-text-grey-600">
              Lowered seizure threshold, peripheral neuropathy, and central neurotoxicity — dose-dependent risks requiring careful titration strategies, EEG monitoring protocols, and contraindication assessment in epilepsy populations.
            </p>
          </div>

        </div>

        <!-- Link to data coverage -->
        <div style="text-align: center; margin-top: var(--space-7);">
          <a href="/platform/data" class="arca-btn-tertiary">
            See Full Neurology Data Coverage <span class="arca-arrow">&rarr;</span>
          </a>
        </div>
      </div>
    </section>

    <!-- SECTION 6: CASE STUDY EXCERPT -->
    <section class="arca-bg-blue-50" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">

          <!-- Left: Case study content -->
          <div>
            <p class="arca-section-label">Case Study — Neurology</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">
              Biogen — Anti-Amyloid Therapy BRA with ARIA Monitoring
            </h2>

            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">
                Biogen's neuroscience safety team needed a comprehensive benefit-risk framework for their anti-amyloid antibody program, integrating ARIA monitoring data across 4 pivotal clinical trials with APOE4 genotype-stratified risk profiling and real-world post-marketing surveillance from early access programs in 23 countries.
              </p>
            </div>

            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Approach</h3>
              <p class="arca-body-sm arca-text-grey-600">
                ArcaScience deployed neurology-specific AI models trained on 6,200+ CNS trials and 15B+ adverse event records, with specialized ARIA detection algorithms integrating MRI imaging frequency data, APOE4 stratification, and cognitive endpoint trajectory modeling using ADAS-Cog and CDR-SB to quantify benefit-risk across patient subpopulations.
              </p>
            </div>

            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="68" data-countup-suffix="%">0</span>
                <p class="arca-caption arca-text-grey-600">Faster ARIA signal characterization</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="4">0</span>
                <p class="arca-caption arca-text-grey-600">Pivotal trials integrated into unified BRA</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="3">0</span>
                <p class="arca-caption arca-text-grey-600">APOE4 risk strata modeled</p>
              </div>
            </div>

            <a href="/evidence/case-studies/neurology-case-study" class="arca-btn-tertiary">
              Read Full Case Study <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

          <!-- Right: Testimonial -->
          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--blue-400);">
              ArcaScience's ability to integrate ARIA monitoring data with cognitive endpoint trajectories gave us a benefit-risk picture we simply couldn't construct manually. The APOE4-stratified risk models were critical for our regulatory discussions with FDA and EMA.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Dr. Elena Vasquez</p>
              <p class="arca-body-sm arca-text-grey-600">VP Neuroscience Safety, Biogen</p>
            </div>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 7: REGULATORY CONTEXT -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Regulatory Intelligence</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">
            Neurology Regulatory Context
          </h2>
          <p class="arca-body-lg arca-text-grey-600">
            Key regulatory considerations and guidance specific to neurology benefit-risk assessment for FDA, EMA, and PMDA submissions.
          </p>
        </div>

        <!-- Accordion for regulatory guidance -->
        <div style="max-width: 820px; margin: 0 auto;">

          <div class="arca-accordion" data-accordion>

            <!-- Accordion item 1 -->
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">FDA Guidance on Neurodegenerative Therapies</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  FDA's 2023 guidance on early Alzheimer's disease and the 2024 draft guidance on neurodegenerative disease drug development emphasize the use of biomarker-based endpoints alongside clinical outcomes. Accelerated approval pathways for amyloid-lowering therapies require robust ARIA monitoring protocols, REMS programs with prescriber certification, and confirmatory trial commitments with long-term cognitive outcome data.
                </p>
                <p class="arca-body-sm arca-text-grey-600" style="margin-top: var(--space-3);">
                  <strong>Key requirements:</strong> ARIA monitoring with serial MRI (baseline, 7 weeks, 14 weeks, and 52 weeks minimum), APOE4 genotyping prior to treatment initiation, C-SSRS suicidality assessment for all CNS-active agents per 2008 FDA class-wide mandate, and patient-reported cognitive and functional outcomes using validated instruments (CDR-SB, ADAS-Cog, ADCS-MCI-ADL).
                </p>
              </div>
            </div>

            <!-- Accordion item 2 -->
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">EMA Guidance for CNS Therapies</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  EMA's CHMP guideline on clinical investigation of medicines for Alzheimer's disease (EMA/CHMP/539931/2014) and the revised guideline on multiple sclerosis treatments require comprehensive benefit-risk assessment with emphasis on long-term safety data, cognitive endpoint validation, and progressive disability outcomes. Conditional marketing authorization for neurodegenerative therapies demands ongoing benefit-risk reassessment at 12-month intervals.
                </p>
                <p class="arca-body-sm arca-text-grey-600" style="margin-top: var(--space-3);">
                  <strong>Key focus areas:</strong> European registry integration for post-authorization safety studies (PASS), health technology assessment (HTA) alignment for reimbursement-linked benefit-risk communication, and PRIME (Priority Medicines) eligibility considerations for breakthrough neurology therapies addressing unmet medical need in neurodegeneration.
                </p>
              </div>
            </div>

            <!-- Accordion item 3 -->
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">REMS Requirements for Neurology Therapies</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  Several neurology drug classes carry Risk Evaluation and Mitigation Strategy (REMS) requirements, including anti-amyloid antibodies (ARIA monitoring with MRI), natalizumab (TOUCH prescribing program for PML risk management), and certain opioid-based neurologic pain therapies. ArcaScience automates REMS compliance monitoring, prescriber certification tracking, and periodic REMS assessment report generation.
                </p>
                <p class="arca-body-sm arca-text-grey-600" style="margin-top: var(--space-3);">
                  <strong>REMS elements supported:</strong> Medication guides, patient package inserts, Elements to Assure Safe Use (ETASU), implementation system design, and REMS assessment reports at FDA-specified milestones including 18-month, 3-year, and 7-year reviews.
                </p>
              </div>
            </div>

            <!-- Accordion item 4 -->
            <div class="arca-accordion-item">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Post-Marketing Requirements for CNS Agents</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">
                  Regulatory authorities globally require ongoing benefit-risk evaluation for neurology therapies through periodic safety reports, long-term cognitive outcome registries, and targeted post-marketing studies. ArcaScience automates PSUR/PBRER generation, signal monitoring, and RMP updates aligned with ICH E2C(R2) and EU GVP Module VIII, with specialized neurology safety signal libraries covering ARIA, PML, suicidality, treatment-emergent movement disorders, and hepatotoxicity signals common to CNS agents.
                </p>
              </div>
            </div>

          </div>

          <div style="text-align: center; margin-top: var(--space-7);">
            <a href="/resources/regulatory-intelligence" class="arca-btn-tertiary">
              View All Neurology Regulatory Updates <span class="arca-arrow">&rarr;</span>
            </a>
          </div>

        </div>
      </div>
    </section>

    <!-- SECTION 8: RELATED RESOURCES -->
    <section class="arca-bg-grey-50" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Resources</p>
          <h2 class="arca-display-sm">Related Neurology Resources</h2>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">

          <!-- Resource 1: Whitepaper -->
          <a href="/resources/whitepapers/aria-monitoring-bra" class="arca-card" style="text-decoration: none; color: inherit; display: flex; flex-direction: column; height: 100%;" data-animate>
            <div style="padding: var(--space-2) var(--space-3); background: var(--blue-50); border-radius: 4px; margin-bottom: var(--space-4); display: inline-block; align-self: flex-start;">
              <span class="arca-label" style="color: var(--blue-600); font-size: 0.625rem; text-transform: uppercase; letter-spacing: 0.05em;">Whitepaper</span>
            </div>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">ARIA Monitoring & BRA: AI-Driven Approaches for Anti-Amyloid Therapies</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-4); flex-grow: 1;">
              Methodology overview for integrating ARIA imaging data with cognitive outcomes in benefit-risk frameworks, including APOE4 stratification and real-world evidence from post-marketing surveillance programs.
            </p>
            <span class="arca-btn-tertiary" style="display: inline-flex; align-self: flex-start;">
              Download Whitepaper <span class="arca-arrow">&rarr;</span>
            </span>
          </a>

          <!-- Resource 2: Blog Post -->
          <a href="/resources/insights/accelerated-approval-neurology-bra-2026" class="arca-card" style="text-decoration: none; color: inherit; display: flex; flex-direction: column; height: 100%;" data-animate>
            <div style="padding: var(--space-2) var(--space-3); background: var(--indigo-50); border-radius: 4px; margin-bottom: var(--space-4); display: inline-block; align-self: flex-start;">
              <span class="arca-label" style="color: var(--indigo-600); font-size: 0.625rem; text-transform: uppercase; letter-spacing: 0.05em;">Insight</span>
            </div>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">The Accelerated Approval Era in Neurology: BRA Implications</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-4); flex-grow: 1;">
              Analysis of how accelerated approvals for Alzheimer's disease therapies are reshaping benefit-risk assessment standards and post-marketing commitments across the neurology landscape.
            </p>
            <span class="arca-btn-tertiary" style="display: inline-flex; align-self: flex-start;">
              Read Article <span class="arca-arrow">&rarr;</span>
            </span>
          </a>

          <!-- Resource 3: Webinar -->
          <a href="/resources/webinars/cognitive-endpoints-bra-webinar" class="arca-card" style="text-decoration: none; color: inherit; display: flex; flex-direction: column; height: 100%;" data-animate>
            <div style="padding: var(--space-2) var(--space-3); background: var(--green-50); border-radius: 4px; margin-bottom: var(--space-4); display: inline-block; align-self: flex-start;">
              <span class="arca-label" style="color: var(--green-600); font-size: 0.625rem; text-transform: uppercase; letter-spacing: 0.05em;">Webinar</span>
            </div>
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Cognitive Endpoint Integration in Neurology BRA</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-4); flex-grow: 1;">
              On-demand webinar covering AI-powered cognitive outcome analysis, disease progression modeling, and benefit-risk communication strategies for neurodegenerative therapy regulatory submissions.
            </p>
            <span class="arca-btn-tertiary" style="display: inline-flex; align-self: flex-start;">
              Watch Recording <span class="arca-arrow">&rarr;</span>
            </span>
          </a>

        </div>

        <div style="text-align: center; margin-top: var(--space-7);">
          <a href="/resources/hub?ta=neurology" class="arca-btn-tertiary">
            View All Neurology Resources <span class="arca-arrow">&rarr;</span>
          </a>
        </div>

      </div>
    </section>

    <!-- SECTION 9: FINAL CTA -->
    <section class="arca-cta-section" data-animate>
      <div style="max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">
          See How ArcaScience Supports Neurology
        </h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">
          Request a demonstration of ArcaScience's platform configured for neurology benefit-risk analysis. Our scientists will walk through CNS-specific data coverage, ARIA monitoring AI models, cognitive endpoint analytics, and REMS assessment output examples relevant to your development program.
        </p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?ta=neurology" class="arca-btn-primary-inverted">
            Request Neurology Briefing
          </a>
          <a href="/platform" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">
            Explore the Platform <span class="arca-arrow">&rarr;</span>
          </a>
        </div>
      </div>
    </section>

  </main>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">

        <!-- Column 1: Brand -->
        <div>
          <img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);">
          <p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">
            AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.
          </p>
        </div>

        <!-- Column 2: Platform -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/platform" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a>
            <a href="/platform/data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a>
            <a href="/platform/decision-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a>
            <a href="/platform/outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a>
            <a href="/platform/security" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a>
          </nav>
        </div>

        <!-- Column 3: Solutions -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/solutions/early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a>
            <a href="/solutions/late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a>
            <a href="/solutions/post-marketing" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Post-Marketing</a>
            <a href="/solutions/therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a>
          </nav>
        </div>

        <!-- Column 4: Company -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/company/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a>
            <a href="/company/team" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a>
            <a href="/company/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a>
            <a href="/company/news" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a>
            <a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a>
          </nav>
        </div>

        <!-- Column 5: Resources -->
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/resources/case-studies" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a>
            <a href="/resources/whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a>
            <a href="/resources/insights" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a>
            <a href="/resources/documentation" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a>
          </nav>
        </div>

      </div>

      <!-- Footer bottom -->
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">
          &copy; 2026 ArcaScience. All rights reserved.
        </p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal/privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal/terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal/cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal/accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <!-- Back to top button -->
  <button data-back-to-top aria-label="Back to top">
    <svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg>
  </button>

  <!-- Global JS -->
  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });

      // Accordion functionality
      document.querySelectorAll('[data-accordion] .arca-accordion-header').forEach(function(header) {
        header.addEventListener('click', function() {
          var content = this.nextElementSibling;
          var icon = this.querySelector('.arca-accordion-icon');
          var isOpen = content.style.display === 'block';

          // Close all accordions in this group
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-content').forEach(function(c) {
            c.style.display = 'none';
          });
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-icon').forEach(function(i) {
            i.textContent = '+';
          });

          // Toggle current accordion
          if (!isOpen) {
            content.style.display = 'block';
            icon.textContent = '\u2212';
          }
        });
      });
    });
  </script>

</body>
</html>
